COA did not say PS-DBM purchase of pandemic supplies 'overpriced' – chair | Inquirer News

COA did not say PS-DBM purchase of pandemic supplies ‘overpriced’ – chair

AS ‘OBSERVATIONS’ IN COA REPORT ‘RELATE MORE TO INVENTORY MANAGEMENT’
/ 01:46 PM September 15, 2021

MANILA, Philippines — Commission on Audit (COA) chairman Michael Aguinaldo clarified Wednesday that their audit report never stated that the purchase of pandemic supplies by the Procurement Service-Department of Budget and Management (PS-DBM) was “overpriced.”

During a hearing of the House committee on good government and public accountability, Aguinaldo explained that “observations” in the COA report “relate more to inventory management than overpricing.”

The House panel is probing the PS-DBM’s purchase of materials for the government’s COVID-19 pandemic response following a COA report flagging the Department of Health’s (DOH) transfer of P42 billion pandemic funds to agencies, including the PS-DBM.

Article continues after this advertisement

In a separate investigation at the Senate, it was revealed that a huge chunk of the funds was used to buy equipment from Pharmally Pharmaceutical Corp., which sold the items at a price higher than other companies.

FEATURED STORIES

“Ang masasabi ko lang po is wala po sa COA report ng PS-DBM ang statement na may overpricing po, there’s no statement to that. The observations relate more to inventory management than overpricing,” Aguinaldo said at the start of the House hearing.

COA did not say DBM-PS purchase of pandemic supplies 'overpriced' – chair

COA chairman Michael Aguinaldo. FILE PHOTO

(What I can say is that it is not stated in the COA report on PS-DBM that there was overpricing, there’s no statement to that. The observations relate more to inventory management than overpricing.)

Article continues after this advertisement

“So hindi po tama na sabihing ang COA ang nagsabi na may overpriced, kasi wala po sinabi ‘yon.  Anyway, nandito po kami to be able to provide clarification to any of the questions the committee members will ask,” he added.

Article continues after this advertisement

(So it is not right to say that COA was the one who said that there was overpricing, because we did not say that. Anyway, we are here to be able to provide clarification to any of the questions the committee members will ask.)

Article continues after this advertisement

The congressional investigations were an offshoot of the COA report that marked deficiencies in the DOH’s spending of its 2020 COVID-19 funds. The COA report likewise highlighted the P42 billion transfers made by the health agency to its procuring partners such as the PS-DBM.

READ: P8.7-B med supply deals went to tiny company

Article continues after this advertisement

Some P8.7 billion of the funds were discovered to have been transferred to Pharmally, which, in the course of the investigations, was found to just have a small capital of P625,000. Consequently, the Senate probe focused on Pharmally, which sold face masks at P27 per piece — compared to another local supplier that sold the same item at only P13 each.

READ: Pharmally exec’s admissions suggest Yang has deep financial ties – Gordon 

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

During the Senate hearings, it was also revealed that what Pharmally did was to ask local and Chinese suppliers to provide the items, which they then delivered to the government.

KGA
TAGS: COA, overpricing, Philippine news updates, PS-DBM

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.